Pharmacokinetics, Pharmacodynamics, and Dosing Considerations of Novel β-Lactams and β-Lactam/β-Lactamase Inhibitors in Critically Ill Adult Patients: Focus on Obesity, Augmented Renal Clearance, Renal Replacement Therapies, and Extracorporeal Membrane Oxygenation.
Dana BakdachReem ElajezAbdul Rahman BakdachAhmed AwaisuGennaro De PascaleAli Ait HssainPublished in: Journal of clinical medicine (2022)
Critically ill patients presenting with special circumstances might be at risk of altered NBLA pharmacokinetics, particularly in the settings of ARC and RRT. More robust, well-designed trials are still required to define effective dose regimens able to attain therapeutic PK/PD indices of NBLA when utilized in those special scenarios, and thus aid in improving the patients' outcomes.
Keyphrases
- extracorporeal membrane oxygenation
- end stage renal disease
- acute respiratory distress syndrome
- ejection fraction
- newly diagnosed
- type diabetes
- escherichia coli
- chronic kidney disease
- metabolic syndrome
- prognostic factors
- peritoneal dialysis
- climate change
- weight loss
- gram negative
- patient reported outcomes
- multidrug resistant
- klebsiella pneumoniae
- adipose tissue
- skeletal muscle
- intensive care unit
- physical activity
- body mass index
- mechanical ventilation
- high fat diet induced